The abstract is read at the publisher; the summary is JClub's.
PFN1 inhibits lytic replication of Kaposi sarcoma-associated herpesvirus by promoting autophagy-lysosomal degradation of the ORF44 helicase, linking PFN1 to selective viral control.
- Why it matters: KSHV lytic replication depends on ORF44, and antiviral strategies that target this step are needed for KSHV-associated malignancies such as KS, PEL, and multicentric Castleman disease.
- What they did: The study showed PFN1 interacts with ORF44 and enhances PFN1 polyubiquitination; TRIM37 facilitates ubiquitination of PFN1 at lysine 116 for recognition by SQSTM1/p62 and subsequent autophagic degradation of ORF44.
- The result: These findings reveal a previously uncharacterized antiviral role for PFN1, suggesting it could be explored as a therapeutic avenue against KSHV-associated malignancies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.